1310 Supporting dose decisions for antibody drug conjugates (ADC) through combined efficacy and toxicity modeling
Main Authors: | Khomveer Singh, Rahul Sing, Bhairav Paleja, Madhav Channavazzala |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
1275 Optimizing lipid nano-particle (LNP) design for mRNA drug delivery, efficacy, and dose prediction using mechanistic modeling
by: Bhairav Paleja, et al.
Published: (2023-11-01) -
ANTIBODY DRUG CONJUGATES (ADCS)
by: E. Terpos
Published: (2023-05-01) -
Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma
by: Ali Al Sbihi, et al.
Published: (2024-02-01) -
Potential of antibody–drug conjugates (ADCs) for cancer therapy
by: Hany E. Marei, et al.
Published: (2022-08-01) -
DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors
by: Xi Li, et al.
Published: (2024-04-01)